Search clinical trials for: RLD2006

Total 45 results

Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Lexeo Therapeutics

Recruiting

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Friedreich Ataxia | Cardiomyopathy, Secondary

United States, Canada
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Hypertension
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
Hanmi Pharmaceutical Company Limited

Completed

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers

Healthy Volunteer

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

Healthy Adult Volunteer

Korea, Republic of
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Hanmi Pharmaceutical Company Limited

Completed

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

Gastritis

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

Gastric Ulcer
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Pfizer

Completed

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

Healthy

Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Pfizer

Completed

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. (B1971016)

Healthy

Spain, United States, Finland, Canada, Denmark, Poland
Pfizer

Completed

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Meningococcal Vaccine

United States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
Pfizer

Completed

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Meningococcal Vaccine

United States, Finland, Czechia, Poland
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Meningitis, Meningococcal

Australia
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Ironshore Pharmaceuticals and Development, Inc

Completed

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Attention-Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD (CEES)

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

Attention Deficit Hyperactivity Disorder

United States

3

Subscribe